New Zealand markets open in 17 minutes

ImmunoPrecise Antibodies Ltd. (IPA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
6.240.00 (0.00%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close6.24
Open6.28
Bid6.23 x 1200
Ask6.50 x 1800
Day's range6.16 - 6.43
52-week range5.05 - 33.34
Volume37,118
Avg. volume293,495
Market cap122.125M
Beta (5Y monthly)-0.16
PE ratio (TTM)N/A
EPS (TTM)-0.46
Earnings date20 Dec 2021 - 24 Dec 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    ImmunoPrecise Announces At-The-Market Facility of up to US$50 Million

    VICTORIA, British Columbia, October 13, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced that it has entered into an At-The-Market Distribution Agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC, as sole sales agent (the "Agent"). Under the ATM Agreement, the Company will be entitled, at its discretion and from time-to-time during the term of the ATM

  • Business Wire

    Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre

    VICTORIA, British Columbia & CASTRES, France, October 07, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) and the Pierre Fabre pharmaceutical group announced today that IPA’s subsidiary, Talem Therapeutics LLC ("Talem"), and Pierre Fabre have entered a multi-year, multi-target research collaboration with the goal to discover and develop therapeutics antibodies for up to nine targets. This strategic collaboration is expected to help expand Talem’s por

  • Business Wire

    ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022

    VICTORIA, British Columbia, September 09, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced financial results for first quarter fiscal year 2022, which ended July 31, 2021.